<DOC>
	<DOCNO>NCT01758328</DOCNO>
	<brief_summary>The purpose study test safety specialize white cell donor different dos . They call WT1 sensitize T cell . They grow lab immunized protein . The protein call Wilms ' tumor protein , WT1 . The multiple myeloma cell make express protein '' . The investigator want learn whether WT1 sensitize T cell attach protein kill myeloma cell . The investigator want find effect , good and/or bad , patient multiple myeloma .</brief_summary>
	<brief_title>Dose Escalation Trial WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Patients With Relapsed/Refractory Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<criteria>Diagnosis : Patient must multiple myeloma either relapse remains refractory follow autologous stem cell transplantation patient plasma cell leukemia diagnosis . Patients relapse multiple myeloma follow autologous stem cell transplantation achieve &lt; partial response follow additional chemotherapy achieve &lt; PR 3 month follow autologous stem cell transplantation patient plasma cell leukemia diagnosis . DONOR : Patients must healthy HLA match mismatch relate unrelated donor willing receive GCSF injection undergo apheresis PBSC collection , undergo marrow harvest procedure . HLAmatched relate unrelated donor Patients HLAmatched relate unrelated donor eligible entry protocol . This include healthy donor genotypically match A , B , C , DRB1 DQB1 locus , test DNA analysis . HLA mismatch related unrelated donor Patients HLAmatched donor relate unrelated donor one antigen one allele mismatch HLA A , B , C , DRB1 DQB1 loci two mismatch , HLADQB1 one locus , eligible entry protocol . The following inclusion criterion also require : Patients â‰¥ 21 , &lt; 73 year old . Patients may either gender ethnic background . Patients must Karnofsky ( adult ) Performance Status &gt; 70 % Patients must adequate organ function measure : 1 . Cardiac : asymptomatic symptomatic LVEF rest must &gt; 50 % must improve exercise . 2 . Hepatic : &lt; 3x ULN ALT &lt; 1.5 total serum bilirubin , unless congenital benign hyperbilirubinemia . 3 . Renal : serum creatinine &lt; 1.2 mg/dl serum creatinine outside normal range , CrCl &gt; 40 ml/min ( measure calculated/estimated ) dose adjustment Fludarabine &lt; 70ml/min . 4 . Pulmonary : asymptomatic symptomatic , DLCO &gt; 50 % predict ( correct hemoglobin ) Each patient must willing participate research subject must sign informed consent form . Female patient pregnant breastfeed Active viral , bacterial fungal infection Patient seropositive HIVI/II ; HTLV I/II Patients previous malignancy remission . Patients know hypersensitivity mouse protein ( murine antibody ISOLEX ) receive SBAE bone marrow , chicken egg product .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>72 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>BUSULFAN</keyword>
	<keyword>FLUDARABINE</keyword>
	<keyword>G-CSF</keyword>
	<keyword>MELPHALAN</keyword>
	<keyword>RABBIT ATG WT1</keyword>
	<keyword>PEPTIDE SPECIFIC T CELLS</keyword>
	<keyword>12-175</keyword>
</DOC>